Updating results

1930 results

Sort: Relevance | Date

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Brolucizumab for treating wet age-related macular degeneration [ID1254]

In development [GID-TA10455] Expected publication date: TBC

Technology appraisal guidance In development

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [ID1583]

In development [GID-TA10530] Expected publication date: 13 May 2020

Technology appraisal guidance In development

Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: 26 June 2020

Technology appraisal guidance In development

Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Technology appraisal guidance In development

PredictSURE-IBD and IBDX to guide personalised treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: 08 July 2020

Diagnostics guidance In development

Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416) [ID1577]

In development [GID-TA10475] Expected publication date: 22 April 2020

Technology appraisal guidance In development

Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Technology appraisal guidance In development

ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

In development [GID-TA10448] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

In development [GID-TA10447] Expected publication date: TBC

Technology appraisal guidance In development

Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 08 July 2020

Technology appraisal guidance In development

Deep brain stimulation for refractory epilepsy

In development [GID-IPG10129] Expected publication date: TBC

Interventional procedures guidance In development

Liraglutide for managing overweight and obesity [ID740]

In development [GID-TA10388] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Testing strategies for Lynch syndrome in people with endometrial cancer

In development [GID-DG10033] Expected publication date: 29 July 2020

Diagnostics guidance In development

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]

In development [GID-TA10460] Expected publication date: 26 February 2020

Technology appraisal guidance In development

Biodegradable balloon insertion for weight loss

In development [GID-IPG10126] Expected publication date: TBC

Interventional procedures guidance In development

Selective internal radiation therapy for unresectable colorectal metastases in the liver

In development [GID-IPG10124] Expected publication date: 26 February 2020

Interventional procedures guidance In development

Ustekinumab for treating moderately to severely active ulcerative colitis [ID1511]

In development [GID-TA10434] Expected publication date: 04 March 2020

Technology appraisal guidance In development

Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: TBC

Technology appraisal guidance In development

Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

In development [GID-TA10494] Expected publication date: TBC

Technology appraisal guidance In development

Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605

In development [GID-TA10488] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [ID1516]

In development [GID-TA10468] Expected publication date: 10 June 2020

Technology appraisal guidance In development

Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

In development [GID-TA10492] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

In development [GID-TA10490] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610

In development [GID-TA10499] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]

In development [GID-TA10498] Expected publication date: 23 June 2021

Technology appraisal guidance In development

Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable ID1564

In development [GID-TA10478] Expected publication date: 10 February 2021

Technology appraisal guidance In development

Fedratinib for splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: TBC

Technology appraisal guidance In development

PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

In development [GID-TA10402] Expected publication date: TBC

Technology appraisal guidance In development

Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Technology appraisal guidance In development

IMCgp100 for treating metastatic uveal melanoma (ID1441)

In development [GID-TA10428] Expected publication date: TBC

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498

In development [GID-TA10420] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

In development [GID-TA10418] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with chemotherapy for untreated extensive-stage small-cell lung cancer ID1509

In development [GID-TA10413] Expected publication date: TBC

Technology appraisal guidance In development

Selinexor with low-dose dexamethasone for treating refractory multiple myeloma ID1535

In development [GID-TA10412] Expected publication date: 06 January 2021

Technology appraisal guidance In development

Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

In development [GID-TA10484] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for treating relapsed or refractory classical Hodgkin's lymphoma after 1 or more multi-agent chemotherapy regimens [ID1557]

In development [GID-TA10485] Expected publication date: 03 February 2021

Technology appraisal guidance In development

Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

In development [GID-TA10486] Expected publication date: TBC

Technology appraisal guidance In development

Darolutamide for treating non-metastatic hormone-relapsed prostate cancer ID1443

In development [GID-TA10476] Expected publication date: 25 November 2020

Technology appraisal guidance In development

Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]

In development [GID-TA10449] Expected publication date: TBC

Technology appraisal guidance In development

Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

In development [GID-TA10465] Expected publication date: TBC

Technology appraisal guidance In development

Encorafenib with binimetinib and cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

In development [GID-TA10479] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Vagus nerve stimulation for treatment-resistant depression

In development [GID-IPG10133] Expected publication date: TBC

Interventional procedures guidance In development

Nintedanib for treating interstitial lung disease caused by systemic sclerosis (ID1420)

In development [GID-TA10427] Expected publication date: TBC

Technology appraisal guidance In development